Such context-specific effects of YAP in RCC progression (e.g., too much or too little YAP causes defective tumor growth) require further clarification as downstream outcomes of YAP may be dependent on TEAD-binding partners (e.g., p65) and the competition in protein–protein interactions which can influence pathogenic outcomes. Here, YAP1 is linked to renal cell carcinoma.